Application of tumor killing effect B cells in treatment and prognosis evaluation of colorectal cancer liver metastasis

By discovering and verifying the meta-CBL of B cell subpopulation with tumor killing effect in colorectal cancer liver metastasis, the neglect of B cells in the prior art is solved, and new prognosis evaluation and treatment methods are provided, which significantly improves tumors The apoptosis rate of cells improves the treatment and prognosis evaluation of liver metastasis in colorectal cancer.

CN118937683APending Publication Date: 2024-11-12SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410949517.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the liver metastasis of colorectal cancer, existing immunotherapy mainly focuses on T cells and NK cells, neglecting the potential anti-tumor effects of B cells, resulting in the lack of effective immune cells in "cold" tumor tissues, poor prognosis, and lack of effective prognosis assessment index.

Method used

A group of B cell subpopulation meta-CBL with tumor killing effect was discovered and verified by 10× single-cell transcriptome sequencing. It was confirmed that it existed in liver metastasis by immunohistochemical staining and flow cytometry, and was verified by in vitro experiments. Its ability to directly kill tumor cells, develop kits and reagents to detect the degree of meta-CBL infiltration as tools for prognostic evaluation and treatment.

Benefits of technology

The degree of meta-CBL infiltration is positively correlated with the prognosis of patients with liver metastasis in colorectal cancer, providing new prognosis evaluation indicators, and in vitro amplification of meta-CBL for cell therapy, significantly improving the apoptosis rate of tumor cells, with Potential anti-tumor treatment value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937683A_ABST
    Figure CN118937683A_ABST
Patent Text Reader

Abstract

The invention relates to the field of tumor immunotherapy and prognosis evaluation, in particular to application of tumor killing effect B cells (meta-CBL) in treatment and prognosis evaluation of colorectal cancer liver metastasis. According to the invention, the fact that metaCBL has potential effector lymphocyte function of killing tumor cells is found for the first time, and metaCBL can be used as one of novel methods for B cell tumor immunotherapy and has good tumor immunotherapy value. Large sample data analysis proves that the meta-CBL cell infiltration degree in the liver metastasis focus is positively correlated with the lifetime of the colorectal cancer liver metastasis patient, so that the infiltration degree of the meta-CBL in the tumor tissue can be used as one of prognosis evaluation indexes of the colorectal cancer liver metastasis patient in pathology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of tumor immunotherapy and prognosis evaluation, and in particular to the application of tumor-killing effector B cells in the treatment and prognosis evaluation of colorectal cancer liver metastasis. Background Art

[0002] Liver metastasis is the leading cause of death in patients with colorectal cancer. Surgical resection of metastases is the most thorough treatment for metastatic tumors. However, only 20%-25% of patients can undergo metastasis resection surgery. Most patients cannot tolerate surgical treatment because the metastases involve large blood vessels or bile ducts, or the metastases are huge or multiple, resulting in insufficient liver function left after resection to maintain the body's survival. Therefore, neoadjuvant tumor therapy based on targeted and immunotherapy has become the preferred method for treating unresectable colorectal liver metastases, with the aim of reducing tumor burden, shrinking tumor lesions, and providing the opportunity for conversion surgery.

[0003] From Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy focusing on T cells, tumor infiltrating lymphocytes (TILs) therapy, to NK cell therapy focusing on natural killer (NK) cells, immune cell therapy has become a unique weapon for tumor immunotherapy. However, in the long-term development of immunotherapy, one of the most abundant immune cells in the human body, B cells, has been overlooked. Previous studies have found that tumor-infiltrating B cells, including initial B cells, memory B cells and terminally differentiated plasma cells, play a multifaceted role in anti-tumor response. The classic B cell anti-tumor mechanism includes: 1. Activating T cell anti-tumor immunity as an antigen processing and presenting cell; 2. Producing tumor-specific antibodies, mediating complement cascade reactions and antibody-dependent cellular cytotoxicity to kill tumor cells. Our research group recently found that there is a group of tumor-killing effector B cells in colorectal cancer liver metastases, which can secrete granzymes GZMA and GZMB effector molecules, and synthesize perforin protein 1 (PFR1) to form immune synaptic gaps, mediate GZMA and GZMB to enter tumor cells, and directly induce tumor cell apoptosis, rather than relying on the tumor-killing function of T cells. Therefore, this type of B cells has potential value in anti-tumor immunotherapy.

[0004] Existing studies have divided solid tumors into “hot” tumors and “cold” tumors based on the degree of infiltration of effector T cells and NK cells in tumor tissues: “hot” tumor tissues are infiltrated with a large number of CD8+ killer T cells and NK cells, and the tumor TNM stage is low, indicating a good tumor prognosis; while “cold” tumor tissues have few or even absent effector T cells and NK cells, often accompanied by a higher TNM stage, indicating a poor tumor prognosis. Recent studies by our research group also found that there is a group of tumor-killing effector B cells with an effector killer phenotype in colorectal cancer liver metastasis tissues, and their infiltration degree is also positively correlated with the prognosis of patients with colorectal cancer liver metastasis. Therefore, the degree of infiltration of this group of cells in liver metastases can be used as one of the pathological indicators for predicting the prognosis of patients with colorectal cancer liver metastases. It is worthy of further application and verification in clinical practice. Summary of the invention

[0005] The purpose of the present invention is to provide the application of tumor-killing effector B cells in the treatment and prognosis evaluation of colorectal cancer liver metastasis.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The present invention conducted 10× single-cell transcriptome sequencing on human colorectal cancer liver metastasis tissue and discovered a group of B lymphocyte subpopulations with a tumor-killing phenotype, which was named meta-CBL. Immunohistochemical staining, flow cytometry, and in vitro cell function experiments all confirmed that meta-CBL existed in liver metastases and directly killed tumor cells by promoting apoptosis. Cell transcriptome functional analysis and in vitro cell co-culture experiments both suggested that meta-CBL has potential anti-tumor therapeutic value.

[0008] At the same time, the present invention found through prognostic analysis of large sample data that the degree of meta-CBL cell infiltration in liver metastases is positively correlated with the disease specific survival (DSS) of patients with colorectal cancer liver metastasis. Therefore, meta-CBL can be used as one of the pathological indicators for evaluating the prognosis of patients with colorectal cancer liver metastasis.

[0009] Based on the above technical solution, the first aspect of the present invention provides the use of a reagent for detecting the infiltration degree of meta-CBL in tumor tissue in the preparation of a kit for evaluating the prognosis of patients with colorectal cancer liver metastasis.

[0010] Furthermore, the reagent for detecting the infiltration degree of meta-CBL in tumor tissue is a reagent for detecting the infiltration degree of meta-CBL in colorectal cancer liver metastasis tissue.

[0011] Furthermore, the reagents for detecting the infiltration degree of meta-CBL in tumor tissue include immunohistochemical reagents for detecting meta-CBL phenotypes CD19, GZMA, GZMB and PFR1.

[0012] Furthermore, the method for detecting the infiltration degree of meta-CBL in metastatic tissue is as follows: tumor tissue is taken, and a multiple fluorescent immunohistochemical staining kit (five colors, including DAPI, 594, 488, CY3, CY5 channels) is used to stain meta-CBL cell marker proteins (CD19, GZMA, GZMB, PFR1), as well as cell nuclei. ImageJ software is used to mark the co-expression of CD19 + GZMA + PFR1 + and CD19 + GZM + PFR1 + cells and CD19 + GZMA + PFR1 + and CD19 + GZM + PFR1 + The B cells were quantitatively analyzed as a quantitative indicator of the infiltration degree of meta-CBL in tumor foci.

[0013] In a second aspect of the present invention, a kit for evaluating the prognosis of patients with colorectal cancer liver metastasis is provided, wherein the kit comprises a reagent for detecting the infiltration degree of meta-CBL in tumor tissue.

[0014] Furthermore, the kit is an immunohistochemistry kit for detecting meta-CBL phenotypes CD19, GZMA, GZMB and PFR1, and the prognosis of the patient is evaluated by semi-quantitatively measuring the infiltration degree of meta-CBL in metastatic lesions.

[0015] Furthermore, the degree of meta-CBL infiltration in colorectal cancer liver metastasis tissue was positively correlated with the DSS of patients with colorectal cancer liver metastasis. The more meta-CBL infiltration in the tumor tissue, the better the patient's prognosis.

[0016] The third aspect of the present invention provides the use of meta-CBL in the preparation of a cell therapy drug for treating colorectal cancer liver metastasis.

[0017] Furthermore, the meta-CBL specifically and highly expresses GZMA, GZMB and PRF1 effector molecules. + GZMA + PFR1 + GZMA +meta-CBL;CD19 + GZM + PFR1 + GZMB + meta-CBL.

[0018] Based on the detection of patient tissue samples and in vitro functional tests, the present invention found that about 20-30% of the B cells in liver metastases belong to the meta-CBL subgroup, and the ability of B cells in metastases to induce apoptosis of tumor cells in vitro is significantly higher than that of B cells colonized in other tissues, and the number of induced apoptosis increases by 3.5 times, suggesting that meta-CBL has a significant function of killing tumor cells. At the same time, GSEA analysis speculates that the killing function of meta-CBL on tumor cells is a pro-apoptotic function mediated by immune synapses (GZMA / GZMB-PRF1). Therefore, after the B cells of the metastases are separated, meta-CBL can be amplified in vitro, and introduced into the tumor site through vector targeting or directly injected into the tumor site to achieve the purpose of eliminating the tumor and reducing the tumor load of the metastatic lesion.

[0019] In the present invention:

[0020] Effector lymphocytes: Lymphocytes undergo transformation and continuous proliferation under antigen stimulation, forming a group of specific lymphocytes related to antigen clearance. They include helper lymphocytes, suppressor lymphocytes and cytotoxic lymphocytes.

[0021] Cytotoxic lymphocytes: a specific effector lymphocyte that secretes various cytokines to participate in immune responses and has a killing effect on certain viruses, tumor cells and other antigenic substances. It is currently believed that cytotoxic lymphocytes mainly include cytotoxic T lymphocytes and natural killer cells, which constitute an important line of defense for the body's antiviral and anti-tumor immunity.

[0022] Granzyme A / B (GZMA / GZMB): Exogenous serine proteases, derived from cytoplasmic granules released by cytotoxic lymphocytes and natural killer cells. Five types of granzymes (GMZA, GMZB, GMZH, GMZK, GMZM) have been found in humans, among which GMZA and GZMB have the strongest activity in inducing apoptosis. When cytotoxic lymphocytes bind to target cells, granzymes enter the target cells and, together with perforin, trigger a cascade reaction in the target cells, causing degradation of target cell DNA and subsequent lysis.

[0023] Perforin 1 (PFR1) is a cytolytic protein that is released from the cytoplasmic granules of killer lymphocytes, forms holes in the target cell membrane, and works synergistically with granzymes to kill target cells.

[0024] The present invention has the advantages that:

[0025] 1. The present invention has discovered and confirmed for the first time a group of B cell subpopulations meta-CBL with killing effects through 10× single-cell sequencing detection combined with in vitro validation experiments. This group of B cells directly kills tumor cells by inducing apoptosis. Therefore, meta-CBL has the potential to kill tumor cells. By using the direct killing effect of meta-CBL on tumor cells, meta-CBL isolated from tissues can be injected into tumor tissues after inducing its proliferation and amplification in vitro, or targeted to tumor cells through vectors, as one of the new methods for tumor B cell therapy. If used in combination with PD-1 / PD-L1 inhibitors, it can fully induce the combined anti-tumor activity of T and B cells, improve the response rate of PD-1 / PD-L1 inhibitor monotherapy, and has strong anti-tumor immunotherapy value.

[0026] 2. The present invention confirms through large sample analysis that the degree of meta-CBL cell infiltration in liver metastases is positively correlated with the patient's DSS. Therefore, the degree of meta-CBL infiltration in tumor tissue can be used as one of the pathological prognostic evaluation indicators for patients with colorectal cancer liver metastasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 :Distribution and characteristics of B cell subsets in liver metastasis tissue of colon cancer: A. UMAP image shows B cell subsets and their distribution in liver metastasis and adjacent normal liver tissue; B. Related gene expression of each B cell subset; CB cell subset Subcluster 7 (meta-CBL) specifically overexpresses GZMA, GZMB and PRF1.

[0028] Figure 2 :Flow cytometry detected the distribution ratio of meta-CBL in primary lesions and liver metastases: A. B cells expressing GZMA in liver metastases accounted for 30.1% of total B cells, which was significantly higher than that in adjacent tumors and primary lesions; B. B cells expressing GZMB in liver metastases accounted for 24.5% of total B cells, which was significantly higher than that in adjacent tumors and primary lesions. (LT: liver metastases; LP: normal liver tissue adjacent to metastases; CT: colon cancer tissue; CP: normal tissue adjacent to colon cancer).

[0029] Figure 3:Direct killing effect of metastatic B cells on tumor cells: A. CCK8 test: Liver metastatic B cells were co-cultured with colon cancer tumor cells SW480 in vitro, which significantly inhibited the proliferation of SW480 cells; B. Flow cytometry apoptosis detection: Metastatic B cells were co-cultured with SW480 cells in vitro, and the number of tumor cell apoptosis induced was significantly higher than that of co-cultured with adjacent paracancerous B cells; C. Gene set enrichment analysis (GSEA) predicted that meta-CBL has the functions of cell killing, inducing apoptosis, and participating in the formation of immune synapse.

[0030] Figure 4 :The degree of tumor infiltration of meta-CBL is positively correlated with the patient's prognosis: Through the survival analysis of 122 patients with colorectal cancer liver metastasis, it was found that the more meta-CBL infiltration in the tumor tissue, the longer the patient's disease specific survival (DSS). DETAILED DESCRIPTION

[0031] The specific implementation methods provided by the present invention are described in detail below in conjunction with examples.

[0032] Embodiment 1:

[0033] 1. Experimental methods

[0034] (1) The cell extraction and flow cytometry analysis process is as follows:

[0035] Take about 0.5cm 3 The tumor tissue was washed twice with PBS to remove residual blood, and the tumor tissue was chopped in a culture dish to a size less than 1 mm;

[0036] Prepare digestion solution: add three enzymes added to the tissue dissociation kit according to the operating instructions to 10 mL RPMI-1640 culture medium;

[0037] Place the digestion solution containing tumor tissue in a 37°C shaker to digest the tissue for 30-40 min, and then add an equal volume of culture medium to terminate the digestion reaction;

[0038] Filter the cells using a 70 μm cell sieve and wash the cells twice with PBS;

[0039] Slowly add 5 mL of lymphocyte separation solution and 5-6 mL of tissue digestion solution to a 15 mL centrifuge tube;

[0040] Set the centrifuge lifting speed (break) to 3 up and 1 down, the centrifugal force to 2500rpm, and centrifuge for 22min at room temperature;

[0041] Carefully aspirate the cells at the interface between the lymphocyte separation solution and the tissue digestion and grinding solution into another 15 mL centrifuge tube (pre-added with 2 mL PBS);

[0042] Centrifugation (9 up and 6 down, 1500 rpm, 10 min);

[0043] Discard the supernatant after centrifugation, add 9 mL of PBS to resuspend the cells, and mix the cell pellet with a 1 mL pipette;

[0044] Centrifugation (9 up and 6 down, 1500 rpm, 10 min);

[0045] Discard the supernatant after centrifugation and resuspend the cells in culture medium.

[0046] (2) CD19 cell magnetic bead (MACS) sorting:

[0047] MACS buffer preparation: PBS + 0.5% FBS + 2mM EDTA;

[0048] MACS buffer 80 μL / 10 7 Resuspend the cells and add 20 μL of Human CD19 MicroBeads per 10 7 cells, incubated at 4°C for 20 min;

[0049] Add 1 mL of MACS buffer to rinse the MS column;

[0050] Resuspend the cells in 2 mL of MACS buffer, place at 4°C, and pass through the MS column;

[0051] After the cell suspension has drained away, add 3 mL of MACS buffer for washing;

[0052] Remove the column and place it in a new 15 mL centrifuge tube. Wash the cells with 2 mL of MACS buffer. Repeat twice.

[0053] The cell suspension in the new centrifuge tube was centrifuged at 350g for 6 min at room temperature, and the supernatant was discarded to obtain CD19 + B cell suspension;

[0054] (3) Flow cytometry analysis: surface fluorescent antibodies and intracellular cytokine detection:

[0055] Add an appropriate amount of cell staining buffer (or PBS containing 1% BSA) to the cells and gently pipette the cells to resuspend them;

[0056] After counting the suspension using a cell counting plate, the cell concentration was adjusted to about 1×10 7 / mL;

[0057] Block Fc receptors: Purified CD16 / CD32 monoclonal antibodies can bind to FcγRⅢ / Ⅱ, block nonspecific staining, and reduce the background fluorescence of negative cells to the level of unlabeled cells. Add 0.5-1μg pure anti-human CD16 / 32 monoclonal antibodies, incubate on ice for 20 minutes, wash with PBS, and centrifuge;

[0058] Staining: During intracellular staining, all working solutions must be placed on ice. First, resuspend the cells with 1 mL of DPBS, add FVS440 antibody (1:1000) to mark cell death and viability, incubate at room temperature and away from light for 15 minutes, then wash with PBS and centrifuge;

[0059] Resuspend the cell pellet with 100-200 μL of Stain Buffer (10 6 Cells), add an appropriate amount of cell surface fluorescent antibody (PE-CD19) to each tube of sample, and incubate at 4℃ in the dark for about 30 minutes. Then add an appropriate amount of PBS to wash the cells, centrifuge at 400g for 6 minutes, discard the supernatant, and then add 1mL of freshly prepared 1× fixation and permeabilization working solution, shake and mix, and incubate on ice in the dark for 40 minutes;

[0060] Directly add 1 mL of 1× membrane permeabilization and cleaning solution, centrifuge at 400 g, 4°C for 6 min, and discard the supernatant;

[0061] Repeat the above steps once, centrifuge at 400g, 4°C for 6 min, and discard the supernatant;

[0062] Resuspend the cells with 100-200 μL of 1× Perm / Wash Buffer, add appropriate amount of human cytokine antibodies (FITC-GZMA, APC-GZMB), etc., vortex to mix, and incubate at 4°C or on ice in the dark for 50 min;

[0063] Gently tilt the tube wall to mix the sample, add 1-2 mL of 1× Perm / Wash Buffer again, centrifuge at 400 g, 4°C for 6 min, discard the supernatant, and repeat this step once;

[0064] Finally, resuspend the cell pellet with 400-500 μL stain buffer, detect on flow cytometer, adjust the flow cytometer voltage, and set the gate.

[0065] Analyze the data.

[0066] 2. Experimental results

[0067] The present invention found that there is a group of B cell subgroups (Subcluster 7) with direct tumor cell killing function in colorectal cancer liver metastasis tissue, and this subgroup is named meta-CBL. meta-CBL specifically overexpresses GZMA, GZMB and PRF1 effector molecules ( Figure 1 ).

[0068] Fresh tissues of primary tumor lesions and liver metastases from patients with colorectal cancer liver metastasis were collected, and CD19-positive B cells were extracted from the two tissues by magnetic bead sorting. Flow cytometry analysis showed that the proportion of meta-CBL subpopulation in liver metastases was significantly higher than that in primary lesions and normal liver tissues ( Figure 2 ).

[0069] The present invention co-cultured metastatic B cells with the highest proportion of meta-CBL with colorectal cancer cells in vitro, confirming that metastatic B cells have a more significant function of inducing tumor cell apoptosis than B cells in other tissues, suggesting that meta-CBL has the ability to directly kill tumor cells. At the same time, GSEA analysis speculates that the killing function of meta-CBL on tumor cells is mediated by the pro-apoptotic function of immune synapse (GZMA / GZMB-PRF1) ( Figure 3 ).

[0070] Furthermore, the present invention mined database information and found through prognostic analysis of 122 patients with colorectal cancer liver metastasis that the infiltration degree of meta-CBL in liver metastatic cancer tissue was positively correlated with the patient's DSS ( Figure 4 ). Therefore, the meta-CBL subpopulation B cells discovered for the first time in the present invention have potential anti-tumor immunotherapy value. At the same time, the infiltration degree of meta-CBL in liver metastases can be used as one of the pathological indicators for evaluating the prognosis of patients with colorectal cancer liver metastases.

[0071] Example 2: Identification method of meta-CBL:

[0072] 1. Co-stain cancer tissue cells through multicomplex IHC staining, the staining targets include: CD19, GZMA, GZMB, PFR1. CD19 + GZMA + PFR1 + GZMA + meta-CBL;CD19 + GZM + PFR1 + GZMB + meta-CBL.

[0073] 2. Identification of meta-CBL by flow cytometry: CD19 magnetic beads isolated from tumor tissue + B cells were loaded onto flow cytometry, gated, and GZMA and GZMB-positive CD19 + The percentage of B cells.

[0074] Example 3: Method for detecting the infiltration degree of meta-CBL in metastatic tissue:

[0075] Liver metastasis tissue was obtained and preserved in 4% formalin. Routine embedding, sectioning, and storage at room temperature were performed for staining. Multiple fluorescent immunohistochemical staining kit (five colors, including DAPI, 594, 488, CY3, CY5 channels) was used to stain meta-CBL cell marker proteins (CD19, GZMA, GZMB, PFR1), as well as cell nuclei. ImageJ software was used to mark the co-expressed CD19 + GZMA + PFR1 + and CD19 + GZM + PFR1 + cells and CD19 + GZMA + PFR1 + and CD19 + GZM + PFR1 + The B cells were quantitatively analyzed as a quantitative indicator of the infiltration degree of meta-CBL in liver metastases.

[0076] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. Application of a reagent for detecting the infiltration degree of meta-CBL in tumor tissue in the preparation of a kit for evaluating the prognosis of patients with colorectal cancer liver metastasis.

2. Use of the reagent for detecting the infiltration degree of meta-CBL in tumor tissue according to claim 1 in preparing a kit for evaluating the prognosis of patients with colorectal cancer liver metastasis, characterized in that: The reagent for detecting the infiltration degree of meta-CBL in tumor tissue is a reagent for detecting the infiltration degree of meta-CBL in colorectal cancer liver metastasis tissue.

3. Use of the reagent for detecting the infiltration degree of meta-CBL in tumor tissue according to claim 2 in preparing a kit for evaluating the prognosis of patients with colorectal cancer liver metastasis, characterized in that: The reagents for detecting the infiltration degree of meta-CBL in tumor tissue include immunohistochemical reagents for detecting meta-CBL phenotypes CD19, GZMA, GZMB and PFR1.

4. Use of the reagent for detecting the infiltration degree of meta-CBL in tumor tissue according to claim 1 in preparing a kit for evaluating the prognosis of patients with colorectal cancer liver metastasis, characterized in that: The degree of meta-CBL infiltration in colorectal cancer liver metastasis tissue is positively correlated with the survival of patients with colorectal cancer liver metastasis. The more meta-CBL infiltration in the tumor tissue, the longer the patient's survival.

5. A kit for evaluating the prognosis of patients with colorectal cancer liver metastasis, characterized in that: The kit includes a reagent for detecting the infiltration degree of meta-CBL in tumor tissue.

6. The kit for evaluating the prognosis of patients with colorectal cancer liver metastasis according to claim 5, characterized in that: The kit is an immunohistochemistry kit for detecting meta-CBL phenotype CD19, GZMA, GZMB and PFR1, and evaluates the patient's prognosis by semi-quantitatively measuring the infiltration degree of meta-CBL in metastatic lesions.

7. Application of meta-CBL in the preparation of cell therapy drugs for the treatment of colorectal cancer liver metastasis.

8. Use of meta-CBL according to claim 7 in the preparation of a cell therapy drug for treating liver metastasis of colorectal cancer, characterized in that: The meta-CBL specifically overexpresses GZMA, GZMB and PRF1 effector molecules.